Inicio・Lista de Acciones・Merck & Co Inc.

Merck & Co Inc.

Abierto

SectorSanidad

127.89 0.42

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

125.21

Máximo

129.94

Métricas clave
By Trading Economics
Ingresos	-7.2B -4.2B
Ventas	-114M 16B
P/B Media del Sector	36.834 64.641
BPA	-1.28
Rentabilidad por dividendo	2.5
Margen de beneficios	-26.053
Empleados	73,000
EBITDA	-6.4B -2B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+7.18% upside

Dividendos
By Acuity
Rentabilidad por dividendo Media del Sector	2.50% 2.31%
Próximas Ganancias	4 ago 2026
Fecha Próximo Dividendo	7 oct 2026
Próxima Fecha de Ex Dividendo	15 sept 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	35B 307B
Apertura anterior	127.47
Cierre anterior	127.89

Noticias sobre sentimiento de mercado

By Acuity

21%

79%

48 / 340 Clasificación en Healthcare

Merck & Co Inc. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 jul 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 jul 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 jul 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 jul 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 jul 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 jul 2026, 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 jul 2026, 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 jul 2026, 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 jul 2026, 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Comparación entre iguales

Cambio de precio

Merck & Co Inc. previsión

Precio Objetivo

By TipRanks

7.18% repunte

Estimación a 12 Meses

Media 136.94 USD 7.18%

Máximo 155 USD

Mínimo 100 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Merck & Co Inc. Dist en los últimos 3 meses.

Sentimiento

By Acuity

48 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.